Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by decrease of the platelet count and increased risk of mucocutaneous bleeding. Multiple factors have been demonstrated in ITP pathogenesis, including the genetic variants. Tumor necrosis factor-induced protein 3 (TNFAIP3) gene encodes the ubiquitin-modifying enzyme A20 which limits inflammation by terminating NF-κB activation through several signaling pathways including TNF and Toll-like receptors and regulates immunostimulatory effects of dendritic cells and attenuates antigen presentation. Single nucleotide polymorphisms (SNPs) of TNFAIP3 have been associated with susceptibilities to several autoimmune diseases. Therefore, we speculated that TNFAIP3 polymorphisms might be associated with the susceptibility of chronic ITP in Chinese population. We investigated the distribution of TNFAIP3 (rs2230926 and rs5029939) polymorphisms in 222 patients with chronic ITP and 153 controls by polymerase chain reaction–restriction fragment length polymorphism and direct sequencing. We observed significant difference in the allelic and genotypic distributions of rs2230926 and rs5029939 between the ITP and control groups (p < 0.05). Stratified analysis by gender revealed the association of rs2230926 polymorphism with chronic ITP in male groups. However, none of the two polymorphisms contributed to the onset age of chronic ITP. These data suggest an association of TNFAIP3 SNPs with susceptibility to chronic ITP. Together with previous reports, our finding provides further evidence for TNFAIP3 being a general autoimmunity gene.
To analyze clinical and molecular characteristics of low-risk essential thrombocythemia (ET) in a large cohort of Chinese patients and to explore risk factors for major thrombosis and treatment strategies. Medical records of patients with an initial diagnosis of ET from March 1982 to May 2012 in our hospital were retrospectively analyzed. A total of 604 low-risk ET patients were enrolled with a median follow-up of 49 months (range:0-338). 43(7.1%) patients experienced major thrombotic events. Cox proportional hazards regression revealed JAK2 V617F mutation (HR=2.279; P=0.035) and cardiovascular risk factors (CVF) (HR=2.541; P=0.006) to be risk factors for total thrombotic events, while only CVF (HR=2.633; P=0.008) was risk factor for arterial thrombosis. None of the evaluated factors was related to venous thrombosis. Patients with both JAK2 V617F mutation and CVF had a worse thrombosis- free survival than those with only one risk factor (P<0.05). In patients with JAK2 V617F or CVF alone, antiplatelet treatment (P=0.016) significantly decreased the risk of thrombosis, while those with both JAK2 V617F and CVF could benefit from cytoreductive agents (P=0.018). Chinese low-risk ET patients have a lower risk of thrombosis than Caucasian low-risk ET patients. JAK2 V617F mutation and CVF are the most significant risk factors for thrombosis. Existence of both risk factors further increases the thrombotic risk. Treatment strategies on low-risk ET patients should be made based on presence or absence of risk factors.
Background: Essential thrombocythemia (ET) is one of the Philadelphia-negative (Ph−) classical myeloproliferative neoplasms (MPNs), characterized by increased megakaryocyte and platelet counts, as well as an increased risk of thrombo-hemorrhagic complications. The JAK2 V617F mutation is detected in 50%–60% of patients with ET and can drive ET occurrence through ligand-independent activation of the thrombopoietin (TPO) receptor, resulting in JAK/STAT pathway signaling. Phosphatase and tensin homolog (PTEN) has been found to be associated with many hematologic diseases, particularly in MPNs, and is involved in the JAK/STAT pathway. This study aimed to determine the role of PTEN in ET patients with the JAK2 V617F mutation.Methods: In this study, we analyzed a series of 32 ET patients without treatment and 25 age- and sex-matched normal controls for the detection of PTEN expression and the STT motif phosphorylation of PTEN, as well as the expression patterns of STAT3 and STAT5 and their phosphorylated molecules (p-STAT3 and p-STAT5, respectively), in bone marrow mononuclear cells (BM-MNCs) by immunohistochemical (IHC) staining of bone marrow biopsies and Western blotting. Correlations between the PTEN expression and other clinical characteristics were also examined.Results: The results showed a downregulated PTEN expression in the BM-MNCs of patients with ET, as well as an elevated p-STAT3 expression and a decreased p-STAT5 expression. In addition, analysis in combination with clinical data demonstrated a negative correlation between the expression of PTEN and the patients’ age and platelet counts. In contrast, a positive correlation was detected between the expression of PTEN and the level of p-STAT5.Conclusions: The results of this study suggest that aberrant PTEN expression and JAK/STAT pathway signaling might be involved in the onset of ET. Our findings could shed new light on the pathogenesis of and the treatment for ET.